The Adherence Self-Efficacy Scale (ASES)<\/strong>\u2014frequently operationalized in chronic disease literature and specialized clinical settings as the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES)<\/em>\u2014is a psychometrically validated, patient-reported outcome measure engineered to evaluate an individual’s perceived behavioral confidence in managing and executing complex treatment plans. Developed by Mallory O. Johnson and colleagues within the context of behavioral medicine and behavioral interventions for chronic disease management, the instrument evaluates self-efficacy across distinct operational domains beyond basic pill-taking routines, including comprehensive dietary regimens, physical activity requirements, symptom monitoring, and navigating healthcare interactions. The instrument comprises 12 primary items structured across two empirically robust dimensions: Adherence Integration<\/em>, which captures a patient’s self-regulatory competence to integrate complex health demands into routine daily life, and Adherence Perseverance<\/em>, which measures the resilience and conviction needed to sustain treatment adherence in the face of physiological, psychological, environmental, or social barriers.<\/p>\n Administered via a graded 11-point visual analogue or Likert-type response continuum ranging from 0 (“Cannot do at all”) to 10 (“Completely certain can do”), the scale yields both domain-specific subscale scores and an overarching composite adherence self-efficacy index. Psychometric evaluations demonstrate exceptional internal consistency across clinical and community samples, with composite and subscale reliability coefficients consistently exceeding $rho = .90$<\/span> and Cronbach’s $\\alpha = .90$<\/span>. Longitudinal assessments establish stability, evidenced by 3-month test-retest coefficients ($r > .70$<\/span>) and 15-month retention coefficients ($r > .40$<\/span>). Exploratory and confirmatory factor analyses confirm a distinct two-factor orthogonal or correlated structure accounting for over 61% of the total variance, characterized by strong factor loadings and high discriminant validity from generalized self-efficacy, depression, and health locus of control. The ASES remains a benchmark clinical trial and observational instrument, serving as a primary target and mediator in psychosocial interventions aimed at improving sustained viral suppression, medical compliance, and long-term quality of life.<\/p>\n Self-Efficacy<\/a>, Treatment Adherence, Antiretroviral Therapy (ART)<\/a>, Adherence Integration, Adherence Perseverance, Health Behavior Change, Psychometrics, Chronic Disease Management, Social Cognitive Theory, Patient-Reported Outcome Measures, Viral Suppression, Behavioral Medicine<\/p>\n The scale was developed and psychometrically validated by a multidisciplinary team of behavioral scientists, psychologists, and clinical epidemiologists from the Center for AIDS Prevention Studies (CAPS) at the Department of Medicine, University of California, San Francisco (UCSF)<\/a>:<\/p>\n Adherence to complex medical regimens constitutes one of the most critical determinants of therapeutic success across chronic infectious and metabolic diseases. In the context of Human Immunodeficiency Virus (HIV) disease, strict adherence to antiretroviral therapy (ART)<\/a> is mandatory to suppress viral replication, halt disease progression, preclude the emergence of drug-resistant viral mutations, and eliminate onward transmission (Undetectable = Untransmittable; U=U). Historically, interventions and clinical assessments treated adherence merely as a mechanical, passive compliance phenomenon, operationalized primarily by pharmacy refill logs or electronic pill-bottle monitoring. However, empirical health psychology demonstrates that medical adherence is an active, dynamic, self-regulatory process dictated by cognitive appraisals, psychological reserves, and environmental resources<\/span>.<\/p>\n The Adherence Self-Efficacy Scale (ASES)<\/strong> was explicitly developed to operationalize, quantify, and evaluate an individual’s situational confidence regarding their ability to execute and maintain comprehensive disease management regimens. While many adherence scales restrict their scope strictly to pill ingestion, the ASES conceptualizes treatment adherence in a holistic framework encompassing:<\/p>\n The ASES serves three core applications in clinical research and healthcare practice:<\/p>\n The Adherence Self-Efficacy Scale measures treatment-specific self-efficacy\u2014an individual’s perceived capability to organize and execute courses of action required to successfully manage a chronic illness under diverse and demanding life circumstances. Rather than treating adherence self-efficacy as a uniform, undifferentiated construct, empirical structural modeling demonstrates that it comprises two distinct but interrelated dimensions: Adherence Integration<\/em> and Adherence Perseverance<\/em>.<\/p>\n Adherence Integration<\/em> reflects the cognitive and operational capability of the patient to assimilate medical demands seamlessly into the fabric of daily life. Chronic care regimens rarely exist in a static vacuum; they require constant coordination with personal routines, work obligations, family duties, sleep-wake cycles, and community demands. Integration encompasses organizational skills, habit formation, prospective memory, and environmental structuring.<\/p>\n Patients with high Adherence Integration demonstrate high self-efficacy in:<\/p>\n Clinical Example:<\/em> An individual with elevated Integration self-efficacy who works rotational shifts formulates systematic cues\u2014such as utilizing synchronized smartphone alarms, automated pill organizers, and meal preparation strategies\u2014ensuring medication is consistently taken on schedule regardless of unpredictable work patterns.<\/p>\n Adherence Perseverance<\/em> captures psychological resilience and distress tolerance under adverse, emotionally exhausting, or structurally disruptive situations. Regimen abandonment frequently occurs not because of poor planning, but because acute stressors\u2014such as medication side effects, interpersonal conflicts, depressive episodes, substance cravings, or fear of stigmatization\u2014overwhelm the individual’s baseline self-regulatory capacity.<\/p>\n Adherence Perseverance assesses the individual’s confidence to persist with treatment when:<\/p>\n Clinical Example:<\/em> A patient struggling with severe episodic emotional distress who scores high on Adherence Perseverance maintains the conviction that they will continue to take their life-sustaining medications and attend clinical appointments even when experiencing depressive apathy, recognizing treatment continuity as vital despite their acute psychological distress.<\/p>\n The Adherence Self-Efficacy Scale is firmly grounded in Albert Bandura<\/a>‘s Social Cognitive Theory (SCT)<\/strong>. Bandura posited that human functioning and behavior are the products of reciprocal determinism\u2014a dynamic, bidirectional interaction among personal cognitive factors, environmental influences, and behavioral patterns. Within this paradigm, perceived self-efficacy<\/a> is the core cognitive engine: it denotes people’s beliefs in their capabilities to exercise control over their own functioning and over events that affect their lives.<\/p>\n A foundational theoretical distinction critical to the ASES architecture is the difference between outcome expectations<\/em> and efficacy expectations<\/em>:<\/p>\n Bandura demonstrated that outcome expectations alone are weak predictors of sustained behavioral change. A patient may fully comprehend that non-adherence leads to treatment failure, drug resistance, and mortality, yet still discontinue treatment if their efficacy expectations are overwhelmed by acute side effects or psychological barriers. The ASES was designed specifically to isolate and quantify these critical efficacy expectations.<\/p>\n According to Social Cognitive Theory, adherence self-efficacy develops and fluctuates through four primary informational sources, which the ASES reflects and measures:<\/p>\n In addition to classic Social Cognitive Theory, the ASES aligns directly with Jeffrey Fisher and William Fisher’s Information-Motivation-Behavioral Skills (IMB) Model<\/a> of adherence. In the IMB framework, adherence-related information and motivation (both personal and social) act primarily through behavioral skills<\/em> to determine objective adherence. Self-efficacy represents the psychological core of behavioral skills: it reflects an individual’s confidence in their ability to enact the specific behavioral skills required for continuous disease management.<\/p>\n The ASES has been subjected to rigorous construct, convergent, discriminant, and criterion-related predictive validity assessments across numerous clinical trials and observational cohorts.<\/p>\n Construct validity was initially established through comprehensive exploratory factor analysis (EFA) and subsequent confirmatory factor analysis (CFA) conducted by Johnson et al. (2007). Structural modeling confirmed that a two-factor structure provided optimal fit to the data, distinguishing between structural lifestyle integration (Adherence Integration) and affective\/situational resilience (Adherence Perseverance). Factor loadings for individual items across both factors ranged robustly from .64 to .88, demonstrating that the items represent coherent, well-defined underlying latent dimensions.<\/p>\n Convergent validity has been repeatedly demonstrated through significant, theoretically coherent associations with established psychosocial and behavioral constructs:<\/p>\n The scale exhibits robust discriminant validity, differentiating adherence self-efficacy from adjacent affective states and global cognitive traits:<\/p>\n The most compelling psychometric validation of the ASES resides in its capacity to predict hard clinical and biological outcomes:<\/p>\n The psychometric evaluation of the ASES reveals exceptional internal consistency and longitudinal stability across diverse clinical settings, socioeconomic strata, and demographic groups.<\/p>\n Across the development and validation cohorts ($N > 400$<\/span>), the HIV-ASES demonstrated internal consistency values that exceed standard psychometric benchmarks for both research and clinical decision-making:<\/p>\n Subsequent validation studies among diverse cohorts\u2014including women of color, individuals with dual diagnoses (substance use and severe mental illness), and multinational cohorts across sub-Saharan Africa and Latin America\u2014have mirrored these findings, reporting composite alpha coefficients consistently above $.88$<\/span>.<\/p>\n Longitudinal evaluation demonstrates that while self-efficacy is sensitive to targeted psychological interventions, it remains structurally stable in the absence of exogenous intervention:<\/p>\n Standard error of measurement (SEM) calculations confirm minimal measurement error, ensuring that clinicians can confidently distinguish true psychological changes from random response variance.<\/p>\n The structural dimensionality of the Adherence Self-Efficacy Scale was delineated using sequential Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) by Johnson and colleagues (2007).<\/p>\n Initial principal components and principal axis factoring with both orthogonal (Varimax) and oblique (Promax) rotations revealed a robust two-factor structure:<\/p>\n Subsequent CFA supported this structural model over alternative single-factor or multi-factor solutions. Representative model fit indices across independent validation cohorts consistently meet or exceed contemporary psychometric standards:<\/p>\n Standardized factor loadings across both latent factors remain uniformly high (predominantly between $.65$<\/span> and $.88$<\/span>), with zero item cross-loadings exceeding $.30$<\/span>. In oblique models, the two latent factors display a moderate-to-high inter-factor correlation ($r \\approx .60$<\/span> to $.70$<\/span>), confirming that while Integration and Perseverance represent distinct clinical targets, they operate as complementary facets of a unified adherence self-efficacy system.<\/p>\n The Adherence Self-Efficacy Scale (ASES) is formatted as a patient-reported psychometric instrument designed for self-administration or interviewer-assisted administration across clinical and field environments.<\/p>\n The Adherence Self-Efficacy Scale was formally published and validated in 2007<\/strong> by Mallory O. Johnson and co-investigators. Developed under research grants funded by the National Institutes of Health (NIH)<\/a>\u2014specifically the National Institute of Mental Health (NIMH)<\/a>\u2014the instrument is generally made accessible for academic research, non-commercial clinical trials, and non-profit educational evaluation.<\/p>\n2. Keywords<\/h2>\n
3. Authors<\/h2>\n
\n
4. Purpose<\/h2>\n
\n
\n
5. Psychological Construct<\/h2>\n
Adherence Integration<\/h3>\n
\n
Adherence Perseverance<\/h3>\n
\n
6. Theoretical Framework<\/h2>\n
Efficacy Expectations vs. Outcome Expectations<\/h3>\n
\n
Sources of Self-Efficacy in Chronic Regimens<\/h3>\n
\n
Integration with the Information-Motivation-Behavioral Skills (IMB) Model<\/h3>\n
7. Validity<\/h2>\n
Construct and Factorial Validity<\/h3>\n
Convergent Validity<\/h3>\n
\n
Discriminant Validity<\/h3>\n
\n
Predictive and Criterion-Related Validity<\/h3>\n
\n
8. Reliability<\/h2>\n
Internal Consistency Reliability<\/h3>\n
\n
Test-Retest Reliability and Stability<\/h3>\n
\n
9. Factor Analysis<\/h2>\n
Exploratory Factor Analysis (EFA)<\/h3>\n
\n
Confirmatory Factor Analysis (CFA) Fit Indices<\/h3>\n
\n
10. Instrument \/ Measurement Tool<\/h2>\n
\n
\n
11. Permissions & Fee and Test Year<\/h2>\n
\n
12. References<\/h2>\n
\n
13. Items of the Scale<\/h2>\n